Canada - English - Health Canada

sterimax inc - milrinone (milrinone lactate) - solution - 1mg - milrinone (milrinone lactate) 1mg - cardiotonic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 9 mg - tablet, modified release - excipient ingredients: sodium chloride; iron oxide red; purified water; hyetellose; macrogol 3350; carnauba wax; butylated hydroxytoluene; polyethylene oxide; povidone; stearic acid; isopropyl alcohol; propylene glycol; iron oxide black; hypromellose; titanium dioxide; macrogol 400; cellulose acetate - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 6 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; sodium chloride; povidone; stearic acid; polyethylene oxide; iron oxide red; hyetellose; macrogol 3350; macrogol 400; carnauba wax; isopropyl alcohol; propylene glycol; cellulose acetate; titanium dioxide; hypromellose; purified water; iron oxide black; iron oxide yellow - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone, quantity: 3 mg - tablet, modified release - excipient ingredients: polyethylene oxide; iron oxide yellow; iron oxide red; butylated hydroxytoluene; purified water; carnauba wax; sodium chloride; hypromellose; iron oxide black; lactose monohydrate; triacetin; stearic acid; povidone; macrogol 3350; titanium dioxide; hyetellose; isopropyl alcohol; cellulose acetate; propylene glycol - invega is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention. invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/or mood stabilizers (lithium and valproate).

Israel - English - Ministry of Health

truemed ltd, israel - pitolisant as hydrochloride - film coated tablets - pitolisant as hydrochloride 17.8 mg - pitolisant - wakix is indicated• in adults for the treatment of narcolepsy with or without cataplexy. • to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa) whose eds has not been satisfactorily treated by, or who have not tolerated, osa primary therapy, such as continuous positive airway pressure (cpap).

Israel - English - Ministry of Health

truemed ltd, israel - pitolisant as hydrochloride - film coated tablets - pitolisant as hydrochloride 4.45 mg - pitolisant - wakix is indicated• in adults for the treatment of narcolepsy with or without cataplexy. • to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa) whose eds has not been satisfactorily treated by, or who have not tolerated, osa primary therapy, such as continuous positive airway pressure (cpap).

Australia - English - Department of Health (Therapeutic Goods Administration)

neolife international pty ltd - glycine max, quantity: 225 mg (equivalent: linolenic acid, qty 16.65 mg); triticum aestivum, quantity: 150 mg (equivalent: gluten, qty 0 mg); triticum aestivum, quantity: 10 mg (equivalent: gluten, qty 0.004 mg); oryza sativa, quantity: 300 mg; oryza sativa, quantity: 10 mg; mixed (high-alpha type) tocopherols concentrate, quantity: 2 mg - capsule, soft - excipient ingredients: gelatin; yellow beeswax; titanium dioxide; chlorophyllin-copper complex; purified water; glycerol - antioxidant/reduce free radicals formed in the body ; maintain/support body metabolism/metabolic rate ; maintain/support energy production ; maintain/support eye health ; maintain/support healthy teeth ; anti-inflammatory/relieve inflammation ; maintain/support connective tissue health ; helps enhance/promote bone health ; maintain/support bone health ; helps enhance/promote healthy joint function ; maintain/support joint health ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support muscle health ; maintain/support muscle function ; helps maintain/support cellular uptake of (state vitamin/mineral/nutrient) ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support brain function ; maintain/support nervous system health ; maintain/support nervous system function

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 12mg (drug layer 1 = 3.6 mg, drug layer 2 = 8.4 mg.) - modified release tablet - 12 mg - active: paliperidone 12mg (drug layer 1 = 3.6 mg, drug layer 2 = 8.4 mg.) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hyetellose hypromellose iron oxide red iron oxide yellow macrogol 3350 macrogol 400 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega prolonged release tablet is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 3mg (drug layer 1 = 0.9 mg, drug layer 2 = 2.1 mg) - modified release tablet - 3 mg - active: paliperidone 3mg (drug layer 1 = 0.9 mg, drug layer 2 = 2.1 mg) excipient: butylated hydroxytoluene carnauba wax cellulose acetate glycerol hyetellose hypromellose iron oxide red iron oxide yellow lactose macrogol 3350 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/ or mood stabilisers (lithium and valproate).

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 6mg (drug layer 1 = 1.8 mg, drug layer 2 = 4.2 mg.) - modified release tablet - 6 mg - active: paliperidone 6mg (drug layer 1 = 1.8 mg, drug layer 2 = 4.2 mg.) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hyetellose hypromellose iron oxide red iron oxide yellow macrogol 3350 macrogol 400 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/ or mood stabilisers (lithium and valproate).